These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 34842621)

  • 1. Introduction to Antibody-Drug Conjugates.
    Pettinato MC
    Antibodies (Basel); 2021 Oct; 10(4):. PubMed ID: 34842621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody Conjugates-Recent Advances and Future Innovations.
    Leung D; Wurst JM; Liu T; Martinez RM; Datta-Mannan A; Feng Y
    Antibodies (Basel); 2020 Jan; 9(1):. PubMed ID: 31936270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.
    Singh D; Dheer D; Samykutty A; Shankar R
    J Control Release; 2021 Dec; 340():1-34. PubMed ID: 34673122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in antibody-drug conjugates: A new era of targeted cancer therapy.
    Sau S; Alsaab HO; Kashaw SK; Tatiparti K; Iyer AK
    Drug Discov Today; 2017 Oct; 22(10):1547-1556. PubMed ID: 28627385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers.
    Peng H
    Antib Ther; 2021 Oct; 4(4):222-227. PubMed ID: 34805745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
    Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
    Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates for cancer.
    Chau CH; Steeg PS; Figg WD
    Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody drug conjugates beyond cytotoxic payloads.
    Hobson AD
    Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review).
    Sun T; Niu X; He Q; Liu M; Qiao S; Qi RQ
    Mol Clin Oncol; 2023 Jun; 18(6):47. PubMed ID: 37206431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
    Chen H; Lin Z; Arnst KE; Miller DD; Li W
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances and Limitations of Antibody Drug Conjugates for Cancer.
    Mckertish CM; Kayser V
    Biomedicines; 2021 Jul; 9(8):. PubMed ID: 34440076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.
    Sheyi R; de la Torre BG; Albericio F
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.
    Anami Y; Xiong W; Gui X; Deng M; Zhang CC; Zhang N; An Z; Tsuchikama K
    Org Biomol Chem; 2017 Jul; 15(26):5635-5642. PubMed ID: 28649690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.
    López de Sá A; Díaz-Tejeiro C; Poyatos-Racionero E; Nieto-Jiménez C; Paniagua-Herranz L; Sanvicente A; Calvo E; Pérez-Segura P; Moreno V; Moris F; Ocana A
    J Hematol Oncol; 2023 Dec; 16(1):118. PubMed ID: 38087293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.